1. Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010;70(5):1970–80.
2. Millennium Pharmaceuticals Inc. Ninlaro® (ixazomib) capsules, for oral use. United States prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf . 2015. Accessed 19 Feb 2017.
3. Australian Register of Therapeutic Goods. Public summary of Ninlaro® ixazomib. Available from: https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=260934&agid=(PrintDetailsPublic)&actionid=1 . Accessed 19 Feb 2017.
4. Ninlaro product monograph. Approved by Health Canada. Available from: https://health-products.canada.ca/dpd-bdpp/item-iteme.do?pm-mp=00035983 . Accessed 19 Feb 2017.
5. Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–34.